Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and ...

Affirm stock is sizzling Friday after the BNPL firm handily beat earnings and revenue estimates in its most recent quarter.

You might resent having to pay premiums, but when disaster or just a minor fender-bender happens, you'll be happy you have ...